May 20, 2019 / 12:00PM GMT
Carter Lewis Gould - UBS Investment Bank, Research Division - Large Cap Biotech Analyst
Great. Good morning. My name is Carter Gould, senior analyst here at UBS covering biotech sector. We're going to kick things off this morning by introducing Molecular Templates. We have the CEO and Founder, Dr. Eric Poma, here. When we look, we have a number of, sort of, antibody-based companies or companies in the antibody space that come across our desk, but I would argue Molecular Templates is one of the definitely unique and novel platforms that we've seen in some time.
Questions and Answers:
Carter Lewis Gould - UBS Investment Bank, Research Division - Large Cap Biotech AnalystAnd so I guess maybe to kick things off, it would be helpful if, Eric, maybe you give us a little bit of background of technology and the company.
Eric E. Poma - Molecular Templates, Inc. - CEO, Chief Scientific Officer & Director
Sure. So the company was founded 10 years ago. Our goal was to really build a new mechanism of action in oncology.